Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, and emerging evidence suggests potential immunomodulatory effects. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.